|
|
|
Insider
Information: |
Coughlin Timothy P |
Relationship: |
Director |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
196,853 |
|
Indirect Shares
|
62,390 |
|
|
Direct
Value |
$19,965,989 |
|
|
Indirect Value
|
$222,119 |
|
|
Total
Shares |
259,243 |
|
|
Total
Value |
$20,188,109 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-74.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Neurocrine Biosciences Inc |
NBIX |
Chief Financial Officer |
2017-02-06 |
137,961 |
|
0 |
Premium* |
|
Travere Therapeutics, Inc |
TVTX |
|
2024-05-08 |
49,000 |
2015-03-31 |
0 |
Premium* |
|
Fate Therapeutics Inc |
FATE |
Director |
2022-06-09 |
9,892 |
2022-06-09 |
56,390 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Director |
2023-05-17 |
0 |
2023-05-17 |
6,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-01-07 |
4 |
AS |
$16.75 |
$1,172,500 |
D/D |
(70,000) |
96,124 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-06-08 |
4 |
AS |
$45.08 |
$2,704,800 |
D/D |
(60,000) |
101,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-06-08 |
4 |
OE |
$2.59 |
$155,400 |
D/D |
60,000 |
161,374 |
0 |
- |
|
FATE |
Fate Therapeutics Inc |
Director |
|
2016-11-23 |
4 |
B |
$2.66 |
$149,997 |
D/D |
56,390 |
56,390 |
2.39 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-03-20 |
4 |
AS |
$44.49 |
$1,779,600 |
D/D |
(40,000) |
101,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-03-20 |
4 |
OE |
$2.59 |
$103,600 |
D/D |
40,000 |
141,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-10-16 |
4 |
AS |
$47.78 |
$1,194,500 |
D/D |
(25,000) |
126,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-12-10 |
4 |
OE |
$2.59 |
$77,100 |
D/D |
20,000 |
107,874 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-12-10 |
4 |
AS |
$21.00 |
$429,500 |
D/D |
(20,000) |
97,874 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-12-18 |
4 |
AS |
$23.11 |
$463,600 |
D/D |
(20,000) |
97,874 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-12-18 |
4 |
OE |
$2.59 |
$51,800 |
D/D |
20,000 |
117,874 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2015-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-07-13 |
4 |
OE |
$5.76 |
$115,200 |
D/D |
20,000 |
121,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-07-13 |
4 |
AS |
$50.00 |
$1,000,000 |
D/D |
(20,000) |
101,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-07-20 |
4 |
OE |
$5.76 |
$115,200 |
D/D |
20,000 |
121,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2015-07-20 |
4 |
AS |
$55.00 |
$1,100,000 |
D/D |
(20,000) |
101,374 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2013-08-21 |
4 |
AS |
$15.05 |
$286,477 |
D/D |
(19,035) |
96,124 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
|
2010-03-01 |
4 |
AS |
$2.53 |
$31,972 |
D/D |
(12,650) |
75,110 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
|
2011-02-28 |
4 |
AS |
$6.83 |
$84,104 |
D/D |
(12,320) |
96,124 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
|
2009-03-30 |
4 |
AS |
$3.43 |
$41,537 |
D/D |
(12,117) |
43,790 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2013-08-05 |
4 |
AS |
$14.99 |
$164,365 |
D/D |
(10,965) |
96,124 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-10-28 |
4 |
AS |
$18.00 |
$180,000 |
D/D |
(10,000) |
97,874 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-10-30 |
4 |
AS |
$18.62 |
$186,200 |
D/D |
(10,000) |
97,874 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-10-31 |
4 |
AS |
$19.00 |
$190,000 |
D/D |
(10,000) |
97,874 |
0 |
- |
|
NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
|
2014-11-28 |
4 |
AS |
$20.14 |
$201,400 |
D/D |
(10,000) |
97,874 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|